Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

GSK PLC closed 20.84% below its 52-week high of £18.24, which the company achieved on May 16th.

Meghan Markle's As Ever logo includes a tribute to Prince Harry. Inside the symbolism and what the Duchess of Sussex has said ...

GSK – Free Report) by 11.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,007 shares of the pharmaceutical company’s ...

GSK’s pentavalent option comes well after vaccine rival Pfizer and its Penbraya hit the market in 2023. That shot similarly mixes components from the company’s other meningococcal vaccines ...

The fund owned 17,324 shares of the pharmaceutical company’s stock after selling 723 shares during the period. DAVENPORT & Co LLC’s holdings in GSK were worth $586,000 at the end of the most ...

combines the immune response-generating components of two of the company's approved vaccines, Bexsero and Menveo, to protect against the five most common strains of meningococcal bacteria, GSK ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

It also gives breathing room for the company ... GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations ...

GSK declined comment, saying, “It is our consistent position that we do not comment on individual shareholders." A short position represents a bet that a company's stock will fall in value.